Roth Capital Initiates ContraFect At Buy

Loading...
Loading...
Analysts at Roth Capital initiated coverage on shares of ContraFect
CFRX
with a Buy rating. The target price for ContraFect is set to $14. ContraFect's shares rose 4.53% to close at $3.46 on Friday.
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsRoth Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...